Compare iShares MSCI Singapore ETF (EWS) vs Recursion Pharmaceuticals Inc (RXRX) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
iShares MSCI Singapore ETF vs Recursion Pharmaceuticals Inc — how do they compare? iShares MSCI Singapore ETF trades at $31.52 (market cap $1.49B), while Recursion Pharmaceuticals Inc trades at $4.1 (market cap $2.14B). The key difference: Recursion Pharmaceuticals Inc is the larger of the two by market cap, and iShares MSCI Singapore ETF is trading nearer its 52-week high, Recursion Pharmaceuticals Inc nearer its low. Which is the better fit depends on your goals — on Pluang, investors hold iShares MSCI Singapore ETF for 45 Days and Recursion Pharmaceuticals Inc for 22 Days on average.
| EWS | RXRX | |
|---|---|---|
Market Cap | $1.49B | $2.14B |
Volume | 2,142,305 | 30,789,535 |
Sector | Broad Market / Factor | Health |
52-Week High | $34.57 | $6.79 |
52-Week Low | $26.71 | $2.84 |
Typical Hold Time | 45 Days | 22 Days |
Enterprise Value | — | $1.66B |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
EWS, the iShares MSCI Singapore ETF, trades at $32.48, down 2.17% amid bearish technical signals. The ETF recently hit a 52-week high, driven by Singapore's economic strength and AI momentum, but faces selling pressure with key support at $32. Financial ratios are unavailable, limiting fundamental clarity.
Outlook remains mixed; Singapore's growth and institutional interest offer upside, but stretched valuations and technical weakness pose risks. Investors should weigh regional economic resilience against potential pullbacks in a volatile market.
RXRX trades at $4.05, down 5.15% today, with a bullish technical signal from moving averages. The company reported revenue of $74.26M in 2025 but a net loss of $644.76M, with negative profit margins. Recent news highlights strategic AI partnerships, including an extended data license with Tempus AI, aiming to fuel long-term growth despite current financial challenges.
The outlook remains speculative; the stock offers exposure to AI-driven drug discovery through a growing pipeline and partnerships, but high cash burn and lack of profitability pose significant risks. Analyst consensus is mixed with 40% buy ratings, reflecting optimism for future catalysts tempered by near-term financial weakness.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
About iShares MSCI Singapore ETF
EWS tracks the MSCI Singapore 25/50 Index, providing targeted exposure to large and mid-cap companies in Singapore. It is heavily weighted toward the financial, industrial, and real estate sectors, serving as a liquid tool for accessing Singapore's stable, dividend-oriented developed economy.
Read more on EWS →About Recursion Pharmaceuticals Inc
Recursion Pharmaceuticals, Inc. is a clinical-stage biotechnology company leveraging artificial intelligence (AI) and machine learning to industrialize drug discovery. The company's unique approach combines one of the world's largest biological and chemical datasets with automated wet-lab and computational systems to map human biology and identify potential therapeutic candidates across a range of diseases, including oncology and rare diseases. Recursion aims to accelerate the traditionally slow and expensive process of drug development.
Read more on RXRX →
